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OBJECTIVES We aimed to clarify the relation between sarpogrelate (SG), a 5-hydroxytryptamine (5-HT)-2
receptor blocker, and myocardial interstitial serotonin or infarct size during ischemia and
reperfusion.
BACKGROUND In cardiac tissues serotonin is rich in vascular platelets, mast cells, sympathetic nerve endings,
and the receptors are present in platelets and cardiomyocytes.
METHODS The myocardial interstitial serotonin levels were measured using a microdialysis technique
during 30-min ischemia with and without SG in in vivo as well as isolated rabbit hearts.
Other rabbits underwent 30 min of ischemia and 48 h of reperfusion, and the effect of SG on
the infarct size was investigated in the absence and presence of a selective protein kinase C
(PKC) inhibitor, chelerythrine (5 mg/kg, intravenously), or a mitochondrial adenosine
triphosphate sensitive potassium (KATP) channel blocker, 5-hydroxydecanoate (5-HD) (5
mg/kg, intravenously). In another series, the effect of SG on PKC isoforms in cytosol and
membrane fraction was assessed after a 20-min global ischemia in isolated rabbit hearts.
RESULTS Interstitial serotonin levels were markedly increased during 30-min ischemia in in vivo and
isolated hearts, and the increases were inhibited by SG in each. The infarct size was reduced
by SG (27 2% vs. 40 3% of control). This effect was blocked by chelerythrine and 5-HD,
respectively. Sarpogrelate further enhanced the ischemia-induced translocation of PKC- to
the membrane fraction.
CONCLUSIONS Sarpogrelate reduces the myocardial infarct size by inhibiting the serotonin release followed
by enhancement of PKC- translocation and opening of the mitochondrial KATP channel in
ischemic myocytes. (J Am Coll Cardiol 2002;40:1347–55) © 2002 by the American
College of Cardiology Foundation
In general, platelets in the vascular beds are rich in serotonin
(5-hydroxytryptamine [5-HT]) in the cytoplasm (1). The
5-HT2A receptors are observed on the cell membranes of
platelets and smooth muscle cells (2,3), and the binding
with released serotonin can induce release of serotonin from
platelet cytoplasm, platelet aggregation, and contraction of
smooth muscle cells (4). These effects are inhibited by
5-HT2 receptor blockers. That is, 5-HT2 receptor blockers
are also inhibitors of serotonin release (5). On the other
hand, 5-HT1 receptors are present on the cell membrane of
endothelial cells, stimulation of which releases endothelial-
derived relaxing factor followed by relaxation of smooth
muscle cells (1). In the cardiac tissues, serotonin has been
identified in platelets in the vascular beds (6), mast cells (7),
and sympathetic nerve endings (8). The 5-HT2 receptors
are not found in the mast cells or sympathetic nerve endings
but are found in the vascular platelets (1). It is postulated
that 5-HT receptors are present in cardiomyocytes, al-
though the function is unclear.
The transcardiac plasma serotonin concentration is in-
creased in some patients with angina pectoris (9). It was
reported that blockade of 5-HT2 receptors by ketanserine
and cinanserine can protect the isolated rat heart against
ischemia in terms of cardiac function (10) and that cinan-
serine has a protective effect on pacing-induced ischemia in
an in vivo model of dogs (11). Sarpogrelate (SG), a selective
5-HT2 receptor blocker, is the only drug, among many
5-HT2 receptor blockers, that is currently clinically used for
patients with arteriosclerotic obliterance. Sarpogrelate may
be protective against human angina pectoris through an
increase in collateral circulation (12). However, the role of
serotonin and 5-HT2 receptor blockers in myocardial isch-
emic cellular damage is unclear. Our hypothesis is as
follows. First, serotonin is released from platelets in the
vascular beds, mast cells, and sympathetic nerve endings at
the area at risk during ischemia and reperfusion, as indicated
by the increase in myocardial interstitial serotonin. Second,
SG can inhibit the serotonin release and the bindings
between serotonin and the 5-HT2 receptor of cardiomyo-
cytes, as indicated by the disappearance of the elevated
myocardial interstitial serotonin levels after treatment with
SG, and, thus, can reduce the infarct size. Therefore, the
aim of the present study was to clarify in rabbit hearts with
minimum collateral circulation: 1) whether the myocardial
interstitial serotonin level is increased during ischemia and
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reperfusion, and, if the increase is blocked by SG; 2)
whether SG can reduce the myocardial infarct size, and if
translocation of protein kinase C (PKC) and opening of the
adenosine triphosphate sensitive potassium (KATP) chan-
nels, which are the main pathways of the protective effect in
ischemic preconditioning (13), are associated with the
infarct size-reducing effect.
METHODS
Protocol 1: myocardial interstitial serotonin in in vivo
and isolated beating hearts. IN VIVO STUDY. Surgical prep-
aration was as previously reported (14). Briefly, rabbits were
anesthetized with sodium pentobarbital (30 to 40 mg/kg,
intravenous), and additional doses were administered when
required throughout the experiment. They were intubated
and ventilated with room air supplemented with low-flow
oxygen using a mechanical ventilator (tidal volume, 20 to 30
ml, respiratory rate, 20/min to 30/min; Model SN-480-5,
Shinano, Tokyo, Japan). Serial blood gas analysis was
performed, and ventilatory conditions were adjusted to keep
the arterial blood gas within the physiologic range. The left
carotid artery and jugular vein were cannulated to monitor
peripheral arterial pressure and to administer drugs or saline.
The rabbits were then systematically heparinized (500
U/kg). A thoracotomy was performed at the third intercos-
tal space, and the heart was exposed after excising the
pericardium. A 4-0 silk suture on a small curved needle was
passed through the myocardium beneath a large marginal
branch of the left circumflex coronary artery, which supplies
much of the anterolateral and apical walls of the left
ventricle (LV). A small vinyl tube was passed into both ends
of the suture to make the snare.
A microdialysis probe (PNF 1700, 20 mm length, 0.31
mm outside diameter, 0.2 mm inside diameter, transverse
type, 50,000 MW cut-off) for dialysate sampling was
implanted in the risk region of the myocardium, which was
served by the anterolateral coronary artery along the axis of
the ventricular fibers and reached from the epicardial outer
layer to the endocardial inner layer of the myocardium. The
probe placement was confirmed at autopsy. The microdi-
alysis probe was perfused with Ringer’s solution at a rate of
10 l/min. After a 60-min rest following the completion of
the instrumentation, the dialysate was sampled during a
30-min period before ischemia and during a 30-min period
of ischemia and during two consecutive 30-min periods of
reperfusion. Ischemia was induced by occluding the coro-
nary branch by pulling the snare, which was then fixed by
clamping the tube with a mosquito hemostat. Myocardial
ischemia was confirmed by regional cyanosis and electrocar-
diographic change. Reperfusion was confirmed by the myo-
cardial blush over the risk area after releasing the snare.
After the initial preparation but before the coronary occlu-
sion, the animals were assigned to one of the two groups
described in the following text.
A total of 14 rabbits underwent 30-min ischemia and
60-min reperfusion in the presence of saline (control group,
n  7) or the 5-HT2 receptor blocker SG (SG group, n 
7; 10 mg/kg/h, intravenous, starting 10 min before ischemia
until 20 min after reperfusion). In the preliminary study
using three rabbits, the plasma concentration of SG in
arterial blood assessed by high-performance liquid chroma-
tography (HPLC) was 588  169 ng/ml and 688  308
ng/ml at 10 min and 60 min, respectively, after the start of
venous infusion of SG at a rate of 10 mg/kg/h. The
concentration was reported to be adequate to block the
5-HT2 receptors (5). Therefore, the dose of 10 mg/kg/h
was selected in the present study.
Isolated heart study. The 12 rabbits were anesthetized and
ventilated as described above. The hearts were excised,
immediately arrested in ice-cold buffer, mounted, and then
perfused at a constant pressure of 100 cm H2O with
Krebs-Henseleit solution gassed with 95% O2 and 5% CO2
at 37°C. After a 20-min stabilization period, the hearts were
perfused with buffer for 30 min and then global ischemia
was induced by stopping the flow of perfusate for 30 min,
and then reperfused for 30 min without ischemia. Sarpogre-
late was administered at a dose of 10 mg/kg/h for 10 min
before global ischemia in six hearts. Another six hearts
without SG were used as controls. A microdialysis probe for
dialysate sampling was implanted in the myocardium along
the axis of the ventricular fibers and reached from the
epicardial outer layer to the endocardial inner layer of the
myocardium. The microdialysis probe was perfused with
Ringer’s solution at a rate of 10 l/min. After a 20-min rest
following the completion of the instrumentation, the dialy-
sate was sampled during a 30-min period before ischemia,
and during a 30-min period of ischemia, and during a
30-min period of reperfusion.
The dialysate samples obtained from both in vivo and
isolated hearts were frozen at 83°C until further analysis.
The dialysate serotonin concentrations were measured using
a reversed-phase HPLC system (MCM column, MC Med-
ical, Tokyo, Japan) coupled with electrochemical detection
(Coulochem II, ESA, Chemsford, Massachusetts).
Abbreviations and Acronyms
ANOVA  analysis of variance
EGTA  ethyleneglycoltetraacetic acid
5-HD  5-hydroxydecanoate
5-HT  5-hydroxytryptamine
HPLC  high-performance liquid chromatography
KATP  adenosine triphosphate sensitive
potassium
LV  left ventricle
PKC  protein kinase C
PMSF  phenylmethylsulfonyl fluoride
SDS-PAGE  sodium dodecyl sulfate-polyacrylamide gel
electrophoresis
SG  sarpogrelate
Tris-HCl  2-amino-2-hydroxymethyl-1,3-
propanedial-HCl
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Protocol 2: infarct size. A total of 110 rabbits underwent
a surgical preparation similar to that in protocol 1 except for
the insertion of the microdialysis probe (Table 1). Two
types of studies (pre-treatment and post-treatment) were
performed. All rabbits underwent 30 min of ischemia
followed by 48-h reperfusion, and the rabbits were ran-
domly assigned to each treatment group by lot. In the
control group (n  15), 1 ml of placebo saline (0.9% NaCl,
pH 7.4) was injected 10 min before ischemia. In the SG
pretreated groups, each rabbit was intravenously infused
with SG at a rate of 5 or 10 mg/kg/h (n  13 and n  12,
respectively), starting 10 min before ischemia until 20 min
after reperfusion for 60 min. In the SG post-treated group
(n  14), SG (10 mg/kg/h) was intravenously infused
starting 10 min before reperfusion until 50 min after
reperfusion for 60 min. In the SG  chelerythrine group
(n 15), chelerythrine (a selective PKC inhibitor, 5 mg/kg)
was intravenously administered 10 min before SG infusion
(10 mg/kg/h  60 min) starting 10 min before ischemia. In
the SG  5-hydroxydecanoate (5-HD) group (n  14),
5-HD (a mitochondrial KATP channel blocker, 5 mg/kg)
was intravenously administered 10 min before SG infusion
(10 mg/kg/h  60 min) starting 10 min before ischemia.
The chelerythrine group (n  13) or 5-HD group (n  14)
was intravenously injected with chelerythrine (5 mg/kg) or
5-HD (5 mg/kg) 20 min before ischemia. After the exper-
iment the chest was closed, and the rabbits were allowed to
recover from anesthesia for two days.
The postmortem examination was as previously reported
(14). At the end of the study, the rabbits were heparinized
(500 U/kg) and killed by an overdose of pentobarbital. The
heart was excised and mounted on a Langendorff apparatus.
The coronary branch was reoccluded, and monastral blue
dye (4%, Sigma Chemical Co., St. Louis, Missouri) was
injected from the aorta at 80 mm Hg. The LV was
sectioned into seven slices parallel to the atrioventricular
ring. Each slice was weighed, incubated in a 1% solution of
triphenyl tetrazolium chloride at 37°C to visualize the
infarct area (15), and photographed. The area of the
ischemic region and the infarcted myocardium were traced
on each LV slice and multiplied by the slice’s weight, then
the infarct size was expressed as a fraction of the risk region
of LV for each heart. The measurement of the infarct size
was performed by two persons blinded to the treatment.
Protocol 3: assessment of the subcellular distribution of
PKC-. The 20 rabbits were anesthetized and ventilated as
described in the preceding text. The hearts were excised,
immediately arrested in ice-cold buffer, mounted, and per-
fused at a constant pressure of 100 cm H2O with Krebs-
Henseleit solution gassed with 95% O2 and 5% CO2 at
37°C. After a 20-min stabilization period, the hearts were
perfused with buffer containing either SG of 10 mg/kg/h
(n  10) or an equivalent volume of saline (n  10) for 10
min. Then, 20-min global ischemia was induced in a half of
each group. Another half of each group (nonischemia
groups) was perfused with buffer for 20 min. We selected 20
min of ischemia because we previously demonstrated that
PKC- is maximally translocated at 20 min of ischemia in
rabbit hearts (16). At the end of the 20-min ischemia, the
ventricles were quickly separated, frozen in liquid nitrogen,
and stored at 83°C.
Frozen samples were weighed and homogenized in five
volumes of buffer containing 300 mM sucrose, 4 mM
N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid, 2
mM ethyleneglycoltetraacetic acid (EGTA), 1 mM phenyl-
methylsulfonyl fluoride (PMSF), and 20 mM leupeptin
using a Polytron homogenizer at the maximum speed in five
5-s bursts. The homogenates were centrifuged at 1,000  g
for 10 min, after which the supernatant was referred to as
the cytosolic fraction. The pellet (membrane fraction) was
dispersed in a buffer containing 20 mM 2-amino-2-
hydroxymethyl-1,3-propanedial-HCl (Tris-HCl), 1 mM
EGTA, 1 mM PMSF, 20 M leupeptin, and 0.5% Triton
X-100. The protein concentration in samples was deter-
mined by the Bradford method (Bio-Rad protein assay kit,
California).
The PKC- present in the cytosolic and membrane
fractions was assessed using a standard sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
Western immunoblotting technique. The proteins (30 mg)
present in each sample fraction were separated by SDS-
PAGE on 8.0% gels and then electrophoretically transferred
to 0.45 m polyvinilidene difluoride membranes using a
Semi-Dry transfer cell (Bio-Rad). The transfer buffer con-
tained 25 mM Tris-HCl and 192 mM glycine in 20%
methanol. The blots were initially blocked overnight with
5% milk in buffer containing 20 mM Tris-HCl (pH 7.4),
137 mM NaCl, 0.05% Tween-20, and then incubated for
Table 1. Ventricular Fibrillation, Death, and Survival in the Experimental Groups
Groups No.
Technical
Exclusion
Occlusion VF
(Total No./No. Nonsurvivors)
Reflow VF
(Total No./No. Nonsurvivors)
Premature
Death
Survivors
(%)
Control 15 1 2/2 1/1 0 11/15 (73)
SG (5 mg/kg/h) pre 13 1 0/0 1/1 0 11/13 (84)
SG (10 mg/kg/h) pre 12 0 1/1 0/0 0 11/12 (91)
SG (10 mg/kg/h) post 14 1 1/1 0/0 1 11/14 (78)
Chelerythrine  SG 15 1 1/1 1/1 1 11/15 (73)
Chelerythrine 13 1 0/0 0/0 2 11/13 (84)
5-HD  SG 14 1 1/1 0/0 1 11/14 (78)
5-HD 14 1 0/0 1/1 1 11/14 (78)
SG  sarpogrelate; VF  ventricular fibrillation; 5-HD  5-hydroxydecanoate.
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1.5 h with anti-PKC- antibody (1:100 dilution). The
primary antibody was monoclonal raised against peptides
corresponding to amino acids 1 to 175 as mapped to the
carboxyterminus of human PKC-. After washing, the blots
were incubated for 1 h at room temperature with a
peroxidase-linked, goat anti-mouse secondary antibody (1:
5,000 dilution). The bound antibody was then visualized
using an enhanced chemiluminescence kit (Amersham).
Protein kinase C was quantified densitometrically using
suitable autoradiographs.
Statistical analysis. Values are expressed as group means
SEM. To compare the group means of the infarct sizes and
quantitation of PKC-, one-way analysis of variance
(ANOVA) was performed, and if the ANOVA results were
significant, a Scheffe´’s post-hoc test was performed. To com-
pare the group means of the hemodynamic parameters, inter-
stitial serotonin levels, a two-way repeated measures ANOVA
followed by a Scheffe´’s post-hoc test was performed. A p value
of 0.05 was considered to be statistically significant.
RESULTS
Mortality and animal exclusion. A total of 110 rabbits
were initially enrolled in the infarct size study. There was no
significant difference in the number of animals assigned to
each of the eight groups or in the incidence and time of
ventricular fibrillation and mortality (Table 1). Among
these animals seven were excluded because of technical
problems, six had ventricular fibrillation during coronary
occlusion, and four had ventricular fibrillation during reper-
fusion; all of these rabbits died. Six rabbits died after the
first day of the experiment. Thus, the experiments were
completed in the remaining 88 rabbits (11 in each of the
eight groups), and the findings from these animals were
used for the analysis.
Hemodynamic parameters. There were no significant dif-
ferences in the basal systolic and diastolic blood pressures
and basal heart rate among any group in protocol 1 (Table
2) and protocol 2 (Table 3). Throughout the experiment the
blood pressure and heart rate were similar among all groups.
Myocardial interstitial serotonin levels. As shown in
Figure 1A, the myocardial interstitial serotonin level in the
in vivo rabbit model significantly increased during 30-min
ischemia and during the first 30-min reperfusion (41.6 
6.7 ng/ml and 47.2  16.6 ng/ml vs. 16.3  3.4 ng/ml at
control), and decreased to below the control level during the
second 30-min reperfusion (7.8  1.9 ng/ml). This increase
in interstitial serotonin during 30-min ischemia and the first
30-min reperfusion was blocked by the pretreatment with
the 5-HT2 blocker SG.
In the isolated heart model, as shown in Figure 1B, the
myocardial interstitial serotonin level before ischemia (0.052
 0.018 ng/ml) was quite low compared with that of the in
vivo model (16.3  3.4 ng/ml), but was significantly
increased during ischemia (1.155  0.427 ng/ml). The
increase disappeared during early reperfusion (0.243 
0.103 ng/ml). The serotonin increases were inhibited by
SG.
Myocardial infarct size. The mean percentages of the area
at risk (percentage of LV) were: 34  1%, 30  3%, 31 
1%, 31  2%, 34  2%, 35  2%, 37  3%, and 37  2%
in the control, SG pre-5 group, SG pre-10 group, SG post
group, SG  chelerythrine group, chelerythrine group, SG
 5-HD group, and the 5-HD group, respectively. No
significant difference was seen among these groups.
As shown in Figure 2, the infarct size as a percentage of
the area at risk was 45  3% in the control group. The SG
pre-5 and SG pre-10 groups showed a significant reduction
in infarct size (31 3% and 27 2%, respectively, p 0.05
vs. the control group). The SG post group did not show a
significant reduction in infarct size (36  2%). Treatment
with chelerythrine and 5-HD blocked the infarct size-
reducing effect of SG, respectively (38  3% and 39  3%,
Table 2. Hemodynamic Parameters (Protocol 1)
Baseline
After
Occlusion
Before
Reperfusion
After
Reperfusion
Systolic blood pressure (mm Hg)
Control 113  8 90  6 86  7 82  9
SG (10 mg/kg/h) pre 95  7 78  5 94  9 78  4
SG (10 mg/kg/h) post 86  4 87  7 72  8 87  2
Diastolic blood pressure (mm Hg)
Control 90  9 73  6 69  7 68  9
SG (10 mg/kg/h) pre 71  6 60  6 75  12 61  5
SG (10 mg/kg/h) post 62  1 68  8 64  5 64  4
Mean blood pressure (mm Hg)
Control 99  9 79  6 73  6 73  9
SG (10 mg/kg/h) pre 80  7 67  6 83  11 67  5
SG (10 mg/kg/h) post 70  2 76  8 74  5 73  3
Heart rate (beats/min)
Control 231  10 240  7 220  7 198  9
SG (10 mg/kg/h) pre 246  13 239  2 232  6 183  7
SG (10 mg/kg/h) post 231  15 248  16 229  22 208  17
After Occlusion  10 min after occlusion; After Reperfusion  20 min after reperfusion; Baseline  immediately before
occlusion; Before Reperfusion  immediately before reperfusion; SG  sarpogrelate.
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respectively). Chelerythrine or 5-HD alone did not affect
the infarct size (38  2% and 41  3%, respectively).
Subcellular translocation of PKC isoform. Protein kinase
C- was detected as a single band with a molecular mass of
98 kDa. The quantitative densitometric analyses illustrated
in Figure 3 showed that 20 min of ischemia caused
translocation of PKC- from the cytosolic to the membrane
fraction and that SG enhanced the ischemia-induced in-
crease in PKC- in the membrane fraction. Sarpogrelate did
not cause any translocation of PKC- in the nonischemic
heart tissue.
DISCUSSION
Release of serotonin into the myocardial interstitial space
during ischemia and the blocking effect by SG. Although
microdialysis technique has been used for the measurements
of adenosine and noradrenaline in the myocardial intersti-
tium during ischemia (16,17,18), no study is published
regarding serotonin, to our knowledge.
The present study revealed an increase in serotonin in
myocardial interstitial tissues during ischemia using micro-
dialysis. In in vivo cardiac tissues, serotonin is rich in platelet
cytoplasm of the vascular beds, although mast cells and
sympathetic nerve endings also have some serotonin (Fig.
4). Ischemia, indicating the lack of blood flow, induces
platelet aggregation and release of serotonin initially. As
platelets have 5-HT2A receptors, their binding with re-
leased serotonin induces a large amount of serotonin release
from platelet cytoplasm and more platelet aggregation. The
presence of 5-HT2 receptors has not been reported in mast
cells or sympathetic nerve endings. The interstitial serotonin
increases were almost completely blocked by SG, a selective
5-HT2 receptor blocker. These findings suggest that an
increase in myocardial interstitial serotonin during ischemia
is merely due to serotonin release from platelet cytoplasm
via the vicious cycle between platelet 5-HT2A receptor and
serotonin rather than the release from mast cells and
sympathetic nerve endings.
In the present study, isolated hearts were perfused with
Krebs-Henseleit solution, which did not include blood or
platelets. The myocardial interstitial serotonin level at the
baseline was quite low, compared with that of the in vivo
hearts. This finding could be explained by platelet washout
due to perfusion with Krebs-Henseleit solution before
ischemia. The myocardial interstitial serotonin level of
isolated hearts was clearly increased during ischemia, al-
though the increase was small compared with that of the in
vivo hearts. One of the possible mechanisms is the release of
serotonin from mast cells and/or sympathetic nerve endings.
However, small amounts of platelets with serotonin would
remain in a part of myocardial capillary beds despite the
washout effect by Krebs-Henseleit solution. The findings of
the present study showed that the increase in myocardial
interstitial serotonin was abolished by SG. These findings
Table 3. Hemodynamic Parameters (Protocol 2)
Baseline
After
Occlusion
Before
Reperfusion
After
Reperfusion
Systolic blood pressure (mm Hg)
Control 132  11 118  11 112  12 108  16
SG (5 mg/kg/h) pre 123  10 111  10 109  14 102  14
SG (10 mg/kg/h) pre 124  11 114  10 110  11 109  13
SG (10 mg/kg/h) post 131  12 116  13 115  10 111  14
Chelerythrine  SG 129  10 110  10 106  12 112  12
Chelerythrine 125  11 111  9 109  10 109  10
5-HD  SG 127  11 114  14 105  10 110  13
5-HD 128  13 113  12 107  15 107  14
Diastolic blood pressure (mm Hg)
Control 84  12 79  14 77  10 80  10
SG (5 mg/kg/h) pre 88  13 82  15 87  12 86  11
SG (10 mg/kg/h) pre 92  11 86  13 86  12 85  14
SG (10 mg/kg/h) post 88  10 78  13 80  10 81  10
Chelerythrine  SG 90  11 83  15 87  12 86  10
Chelerythrine 86  12 78  13 80  10 79  8
5-HD  SG 92  16 86  10 80  10 87  13
5-HD 87  10 80  10 87  12 81  10
Heart rate (beats/min)
Control 222  21 229  22 228  12 231  10
SG (5 mg/kg/h) pre 228  14 227  17 233  17 225  10
SG (10 mg/kg/h) pre 227  13 224  12 230  18 218  13
SG (10 mg/kg/h) post 220  22 228  12 229  18 233  14
Chelerythrine  SG 234  14 230  12 234  12 225  15
Cheleruthrine 222  20 231  18 235  10 238  10
5-HD  SG 230  18 233  16 226  15 225  14
5-HD 232  12 221  19 233  19 232  12
After Occlusion  10 min after occlusion; After Reperfusion  20 min after reperfusion; Baseline  immediately before
occlusion; Before Reperfusion  immediately before reperfusion; 5-HD  5-hydroxydecanoate; SG  sarpogrelate.
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suggest that the serotonin release from the remaining
platelet via the vicious cycle plays an important role in the
increase of myocardial interstitial serotonin in isolated
hearts during ischemia.
In in vivo hearts, the increase in interstitial serotonin was
observed during early reperfusion and disappeared thereaf-
ter. On the other hand, the increase was not seen even
during early reperfusion in isolated hearts. This suggests
Figure 1. (A) Myocardial interstitial serotonin levels before, during 30-min ischemia, and during two consecutive 30-min reperfusions in the absence and
presence of sarpogrelate in an in vivo model. Myocardial interstitial serotonin levels were significantly increased during ischemia and the first 30-min
reperfusion. These increases were inhibited by sarpogrelate. Vertical axis: eluate concentration (ng/ml). *p  0.05 versus baseline control. (B) Myocardial
interstitial serotonin levels before, during 30-min ischemia, and during 30-min reperfusion in an isolated heart model with and without sarpogrelate.
Myocardial interstitial serotonin levels were significantly increased during ischemia without sarpogrelate. Sarpogrelate completely abolished the increase in
myocardial interstitial serotonin during ischemia. Vertical axis: eluate concentration (ng/ml). *p  0.05 versus baseline control.
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that the increase during early reperfusion in in vivo hearts
depends on blood reperfusion with platelets. That is, aggre-
gation of new reperfused platelets and serotonin release
from these may be important.
Translocation of myocardial PKC- and myocardial in-
terstitial serotonin in isolated hearts. Protein kinase C
consists of various subtypes and is present in various types of
cells, especially rich in blood cells. Furthermore, rapid
freezing in liquid nitrogen is needed for the precise mea-
surement. Therefore, we used isolated hearts perfused with
Krebs-Henseleit solution, but not in vivo hearts, for the
measurement of myocardial PKC, as previously reported
(19). The findings of this study in isolated hearts that
PKC- was translocated from the cytosolic fraction to the
membrane fraction during ischemia confirmed the previous
observation (19). In the present study we found that SG, a
5-HT2 receptor blocker, enhanced translocation of myocar-
dial PKC- and inhibited the increase in myocardial inter-
stitial serotonin during ischemia in isolated hearts. This
suggests that increased translocation of myocardial PKC-
may be associated with inhibition of myocardial interstitial
serotonin (Fig. 4).
Possible mechanisms of the infarct size-reducing effect
by SG. Sarpogrelate significantly reduced the myocardial
infarct size in in vivo rabbit hearts. Because SG had no effect
on heart rate or blood pressure, the infarct-size-reducing
effect of SG was not due to the decrease in the double
product, an indicator of oxygen demand. In addition, the
infarct size-reducing effect of SG was independent of the
regional blood flow because the collateral circulation in the
rabbit heart was minimal (20).
Cardiomyocytes are protected against ischemic cellular
damage via translocation of PKC- in isolated rabbit hearts,
followed by opening of the mitochondrial KATP channel
(13,21), which was confirmed in this study. The findings of
this study showed an increase in myocardial interstitial
serotonin during ischemia and reperfusion, which was
inhibited by SG, a selective 5-HT2 receptor blocker, as
discussed previously. Sarpogrelate enhanced further trans-
location of PKC- and reduced infarct size. The infarct-
size-reducing effect of SG disappeared after treatment with
chelerythrine, a selective PKC inhibitor, and with 5-HD, a
selective inhibitor of the mitochondrial KATP channel.
These findings suggest that increased myocardial interstitial
Figure 2. Infarct size as a percentage of the area at risk (AAR). Sarpogrelate (SG) pretreated group: SG was infused at a rate of 5 or 10 mg/kg/h starting
10 min before ischemia until 20 min after reperfusion for 60 min. Sarpogrelate post-treated group: SG was infused at a rate of 10 mg/kg/h starting 10 min
before reperfusion until 50 min after reperfusion for 60 min. Sarpogrelate (5 and 10 mg/kg/h) reduced the infarct size, which was blocked by a selective
protein kinase C inhibitor, chelerythrine, or a mitochondrial adenosine triphosphate sensitive potassium channel blocker, 5-hydroxydecanoate (5-HD).
Chelerythrine or 5-HD alone did not affect the infarct size. *p  0.05 versus control.
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Figure 3. Quantitation of protein kinase C- in the cytosolic and membrane fractions in the control, control  sarpogrelate, ischemia, and sarpogrelate 
ischemia groups. *p  0.05.
Figure 4. Role of serotonin in ischemia and reperfusion and the possible mechanism of the infarct size-reducing effect by sarpogrelate. Serotonin
(5-hydroxytryptamine [5-HT]) is released from cardiac tissues within the area at risk, such as platelets in the vascular beds, mast cells, and sympathetic nerve
endings, in ischemia and reperfusion. The increase in myocardial interstitial serotonin induces the release of a large amount of serotonin from platelet
cytoplasm and platelet aggregation via 5-HT2A receptor on the cell membrane of platelets (#), and the myocardial interstitial serotonin is further increased.
Note the presence of a vicious cycle among the released serotonin, 5-HT2A receptors, on the cell membrane of platelets and rich serotonin in platelet
cytoplasm. Sarpogrelate, 5-HT2 receptor blocker, inhibits the binding between released serotonin and 5-HT2A receptors on the cell membrane of platelets
and blocks the increase in interstitial serotonin by breaking the vicious circle. Translocation of protein kinase C (PKC)- from the cytosolic to the membrane
fraction followed by opening of the mitochondrial adenosine triphosphate sensitive potassium channel is an intrinsic protective mechanism of
cardiomyocytes against ischemic damage. The released serotonin during ischemia inhibits the translocation of PKC- (*). Sarpogrelate further enhances
translocation of PKC- followed by opening of the mitochondrial adenosine triphosphate sensitive potassium channel and reduces infarct size via inhibition
of serotonin release.
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serotonin can inhibit translocation of PKC- followed by
opening of the mitochondrial KATP channel, and SG
reduces infarct size by inhibiting an increase in serotonin
release during ischemia and reperfusion (Fig. 4).
Other possible mechanisms of the infarct size-reducing
effect by SG are as follows. Stimulation of 5-HT2 receptors
by serotonin accumulates inositol phosphates through phos-
pholipase C-mediated hydrolysis of phosphoinositides (22),
which can release calcium from intracellular pools, and may
cause calcium overload and damage the myocytes (23).
Serotonin induces vasoconstriction and thrombus formation
in intramyocardial small vessels, and may cause the so-called
no-reflow phenomenon (24). The calcium overload and
so-called no-reflow phenomenon are associated with early
reperfusion injury. In this study serotonin was increased not
only during ischemia, but also during early reperfusion, and
the increases were inhibited by SG. Therefore, the inhibi-
tion of calcium overload and the so-called no-reflow phe-
nomenon may be included in the protective mechanism of
SG.
Clinical implications. Sarpogrelate is currently used for
the treatment of patients with arteriosclerosis obliterance
because of its vasodilating and antiplatelet actions. It has
been reported that SG is beneficial for human angina
pectoris through an increase in the collateral circulation
(12). In this study we found a cardioprotective effect against
infarction, which was independent of collateral flow or
double products. The doses of SG used in this study were 5
or 10 mg/kg/h, and plasma concentrations of SG 10 and 60
min after infusion of 10 mg/kg/h of SG was 588 and 688
ng/ml, respectively. The clinical dose of SG is 100 mg  3
times/day, and the maximum plasma concentration of SG
after oral administration of 100 mg of SG was reported to
be 540 ng/ml in healthy volunteers (25), which is very
similar to that of the present study. In the present study SG
reduced myocardial infarct size only when administered
before ischemia. Therefore, SG may be useful for reducing
infarct size when acute myocardial infarction occurs in the
patients with angina pectoris and atherosclerosis obliterance
that have previously been being treated with SG. Further
clinical investigations are warranted.
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